Related Experiment Video

Updated: Apr 21, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

651

[Axitinib in metastatic renal carcinomas: update of knowledge about side effects]

Laurence Albiges1, Hassan Izzedine2, Stéphane Ederhy3

  • 1Institut Gustave-Roussy, Département d'oncologie médicale, 39, rue Camille-Desmoulins, 94805 Villejuif cedex, France.

Bulletin Du Cancer
|November 7, 2014
PubMed
Abstract

Insights

Axitinib, a targeted therapy for metastatic renal cell carcinoma, presents a manageable side effect profile compared to other tyrosine kinase inhibitors. New guidance focuses on managing specific ENT side effects and polycythemia.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Practice Guidelines

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment often involves targeted therapies.
  • Axitinib is a tyrosine kinase inhibitor (TKI) used in mRCC treatment.
  • Previous clinical practice guidelines (2011) addressed toxicities of targeted therapies, including axitinib.

Purpose of the Study:

  • To summarize current knowledge on axitinib's side effects: incidence, etiology, and symptoms.
  • To identify axitinib-related side effects requiring specific management.
  • To update management strategies for axitinib toxicities in mRCC.

Main Methods:

  • Review of existing clinical practice recommendations from 2011.
  • Analysis of side effect profiles of axitinib compared to other TKIs.
  • Assessment of changes in management and follow-up protocols since 2011.

Main Results:

  • Axitinib demonstrates a favorable toxicity profile relative to other TKIs.
  • Increased frequency of Ear, Nose, and Throat (ENT) side effects and polycythemia noted with axitinib.
  • No major changes in the overall management and follow-up of axitinib side effects since 2011.

Conclusions:

  • Current management of axitinib side effects aligns with 2011 recommendations.
  • Preventive measures and management strategies for ENT side effects and polycythemia require integration into updated guidelines.
Keywords:
axitinibmetastatic renal cell carcinomarecommendationsside effectstyrosine kinase inhibitors

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.3K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
547
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
811
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
660
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K